Frederique Spyratos

Title: Frederique Spyratos: Innovator in Cancer Treatment Prediction

Introduction

Frederique Spyratos is a notable inventor based in La Celle St. Cloud, France. She has made significant contributions to the field of cancer treatment, particularly in predicting the outcomes of anthracycline therapy for patients with cell proliferative disorders. Her innovative work has the potential to improve treatment efficacy and patient outcomes.

Latest Patents

Frederique holds 1 patent for her invention titled "Markers for the prediction of outcome of anthracycline treatment." This patent describes methods for predicting the effectiveness of anthracycline treatment by determining the expression levels of specific genes, including PITX2, TFF1, and PLAU. The invention also encompasses sequences, oligonucleotides, and antibodies that can be utilized in these predictive methods.

Career Highlights

Frederique is currently associated with Therawis Diagnostics GmbH, where she continues her research and development efforts. Her work is pivotal in advancing the understanding of cancer treatment and enhancing therapeutic strategies.

Collaborations

Frederique has collaborated with esteemed colleagues, including John Foekens and John W Martens, to further her research initiatives. These collaborations have enriched her work and contributed to the broader scientific community.

Conclusion

Frederique Spyratos is a pioneering inventor whose work in predicting cancer treatment outcomes is making a significant impact in the medical field. Her innovative approaches and collaborations are paving the way for advancements in cancer therapy.